A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Clinical trial NCT01973387 · COMPLETED

Trial details

NCT number: NCT01973387
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2013-10-28
Primary completion: 2015-12-01
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.